Regulatory News
Thursday, April 21, 2016
AbbVie gets option on early Argenx cancer drug for $40 mln
April 21 (Reuters) - AbbVie has acquired an option
on an early-stage immuno-oncology drug from biotech company
Argenx, giving the U.S. drugmaker access to a
treatment with the potential to block a...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment